UNSPSC 51282930: Miloxacin

This classification denotes an antibiotic with the molecular formula C12H9NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VM4W7043SN, chemically known as 5,8-dihydro-5-methoxy-8-oxo-2h-1,3-dioxolo(4,5-g)quinoline-7-carboxylic acid but generally known as miloxacin, which bears US NIH Compound Identifier 37614. European Medicines Agency schedules Miloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08967MIG.

UNSPSC 51282930 Miloxacin, a Commodity code, does not map clearly to the state and local opportunities currently being solicited under this tag. The recent solicitations capture pharmaceutical procurement broadly — naloxone, generic multi-source drugs, over-the-counter products, and direct-to-manufacturer prescription programs — but none specifically target miloxacin (a fluoroquinolone antibiotic). The mismatch between the code's narrow scope and the breadth of actual pharmaceutical buying suggests this Commodity code sees little activity or receives inconsistent tagging in practice.

The issuing bodies pursuing pharmaceutical procurement span health departments, public health agencies, cooperative purchasing alliances, and fire-rescue divisions across multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers and comply with Good Manufacturing Practices and Drug Supply Chain Security Act standards. Seminole County, Florida solicited naloxone and safe drug deactivation systems through an IFB (IFB60459723LAS) due July 26, 2023, with quarterly deliveries to the county's community health building. The City of Tampa's Purchasing Department issued an IFB for medical and first aid supplies (Bid 26-P-00145) with an estimated contract amount of $700,000 and a response deadline of March 13, 2026, designated as a sheltered market opportunity for certified Small Local Business Enterprises. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on March 27, 2026 with a response deadline of April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription contracting. Geographic activity spans Florida, Texas, Minnesota, and Oregon, though the recent opportunities block shows no sustained procurement specifically under the miloxacin Commodity code.